194 related articles for article (PubMed ID: 25488073)
21. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
23. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
[TBL] [Abstract][Full Text] [Related]
24. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
26. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
[TBL] [Abstract][Full Text] [Related]
27. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
Norden AD; Bartolomeo J; Tanaka S; Drappatz J; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Quant EC; Beroukhim R; Wen PY
J Neurooncol; 2012 Jan; 106(1):121-5. PubMed ID: 21706358
[TBL] [Abstract][Full Text] [Related]
28. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
[No Abstract] [Full Text] [Related]
29. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
32. Interaction between Vascular Endothelial Growth Factor-A (rs2010963) Gene Polymorphisms and Dietary Diversity Score on Cardiovascular Risk Factors in Patients with Metabolic Syndrome.
Abbasalizad Farhangi M; Vajdi M; Nikniaz L; Nikniaz Z
Lifestyle Genom; 2020; 13(1):1-10. PubMed ID: 31786572
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I
Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
36. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Badaoui N; Meyronet D; Cartalat-Carel S; Guyotat J; Jouanneau E; d'Hombres A; Sunyach MP; Jouvet A; Louis-Tisserand G; Archinet A; Frappaz D; Bauchet L; Honnorat J; Ducray F
Rev Neurol (Paris); 2014 Mar; 170(3):222-7. PubMed ID: 24582303
[TBL] [Abstract][Full Text] [Related]
37. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors.
Jiang X; Zhang QL; Liu TG; Zhao WP; Yang M; Wang LN; Sun WL; Pan L; Luo AP; Huang JC; Gu XH
Curr Pharm Des; 2019; 25(8):862-870. PubMed ID: 30848190
[TBL] [Abstract][Full Text] [Related]
40. Calcification in high grade gliomas treated with bevacizumab.
Blumenthal DT; Aisenstein O; Ben-Horin I; Ben Bashat D; Artzi M; Corn BW; Kanner AA; Ram Z; Bokstein F
J Neurooncol; 2015 Jun; 123(2):283-8. PubMed ID: 25939440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
